ESUI17: Improving management strategies in bladder cancer treatment

23 August 2017

ESUI16 Podium discussion aa

Advances in the management of urological cancers particularly the role of imaging in bladder cancer diagnosis and treatment are one of the key topics in the agenda of the 6th EAU Section of Urological Imaging (ESUI17) Meeting on November 16 in Barcelona.

“There are key issues that need to be examined and discussed such as the role of MRI in the local staging of bladder cancer. Questions such as how we can optimise new technology or what we need to be aware of in terms of limitations and potentials,” said ESUI Chairman Prof. George Salomon (DE).

With “New Technologies and Limited Resources” as the meeting’s main theme, the ESUI will closely look into optimal management strategies in prostate, renal and bladder cancers to provide an update on best practices. Held in conjunction with the 9th European Multidisciplinary congress on Urological Cancers (EMUC), ESUI17 will feature various formats such as point-counterpoint debates, thematic roundtable discussions and Q&A forums.

Salomon noted the bladder cancer (BCa) session will feature speakers who will discuss both standard and innovative practices that aim to improve BCa therapy. Prof. Marek Babjuk (CZ) will speak on the standard work-up for microhaematuria, focusing on current recommendations in the EAU guidelines. Speakers will also take up MRI in the local staging of bladder cancer and present insights on how this technology can help doctors in decision-making and improve their treatment plan. Max Kriegmaier (DE) will discuss multiparametric cystoscopy to underscore the potentials in imaging techniques.

Joint ESUI-EANM session

Aside from the review or assessment of clinical practices, the ESUI programme also features a joint session with the European Association of Nuclear Medicine (EANM) to focus on molecular imaging. The issues of cost-effectiveness and improvement of cancer control using PET/CT will be examined by Stefano Fanti (IT) who will open the session. Other topics include the use of fluciclovine-PET in managing prostate cancer, the role of PSMA and the androgen receptor in improving treatment monitoring of metastatic PCa, and new PET-tracers for renal cell cancer.

“With our aim to broaden the scope of discussion, we hope to stimulate a critical examination of standard and emerging therapies and practices. By carefully re-considering key issues and challenges, we can prompt all participants to exchange ideas and new approaches,” Salomon said.

He also reiterated the ESUI’s goal to nurture innovative research by presenting the Abstract Sessions where the best will be recognised with the Best Abstract Award and a cash prize of €1,000. The six top-ranked posters will be presented during the session followed by short discussions. Following the presentations the jury will decide on the winner. Clinical research fellow Dr. Joana Neves won last year the Best Poster Award for her research “Combining mpMRI sequences for the diagnosis of prostate cancer – the value of adding diffusion and contrast enhancement to T2W on 3Tesla: Outcomes from the PICTURE trial” during the 5th ESUI Meeting held in Milan.

For additional details, check the Scientific Programme, registrations and other meeting information in this website. Online registration is open with the late fee registration applicable from 15 August to 16 November.